ReCode Therapeutics Appoints Trisha Millican to Board of Directors

Veteran life sciences industry financial executive appointed as independent member of the Board of Directors Menlo Park, Calif. and Dallas, Texas – December 1, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of Patricia “Trisha” Millican to […]

ReCode Therapeutics to Present at Upcoming Investor Conferences in 2022

Menlo Park, Calif. and Dallas, Texas – November 22, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Company leadership will participate in two upcoming investor conferences in November: Piper Sandler 34th Annual Healthcare ConferenceFormat: Company PresentationDate: Tuesday, November […]

ReCode Therapeutics Establishes Scientific Advisory Board

Members include distinguished academic and industry leaders with expertise in genetic medicine, delivery technology and drug development Menlo Park, Calif. and Dallas, Texas – November 14, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the formation of the company’s […]

ReCode Therapeutics to Participate in Upcoming November Investor Conferences

Menlo Park, Calif. and Dallas, Texas – November 2, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Company leadership will participate in two upcoming investor conferences in November: Credit Suisse 31st Annual Healthcare ConferenceFormat: Company PresentationDate: Wednesday, November […]

ReCode Therapeutics to Participate in Upcoming October Investor Conferences

Menlo Park, Calif. and Dallas, Texas – September 26, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Company leadership will participate in two upcoming investor conferences in October: Chardan’s 6th Annual Genetic Medicines ConferenceFormat: Company PresentationDate: Monday, October […]

ReCode Therapeutics to Present at Jefferies Cell and Genetic Medicine Summit

Menlo Park, Calif. and Dallas, Texas – September 22, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that David Lockhart, Ph.D, President and Chief Scientific Officer of ReCode Therapeutics, will present a company overview at 8:00 a.m. ET on […]

ReCode Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

MENLO PARK, Calif. & DALLAS–(BUSINESS WIRE)–ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics, will present a corporate overview at 8:00 a.m. ET on Tuesday, September 13th at the upcoming […]

ReCode Therapeutics to Participate in Upcoming July Investor Conferences

Menlo Park, Calif. and Dallas, Texas – July 6, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that Company leadership will participate in two upcoming investor conferences in July: William Blair Biotech Focus Conference (New York, NY)Format: Panel PresentationDate: […]

ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M

– Series B extension co-led by AyurMaya, an affiliate of Matrix Capital Management, and Leaps by Bayer, with participation from Amgen Ventures. Adds to Existing Investors, including Pfizer Ventures, EcoR1 Capital and Sanofi Ventures. –  – Proceeds to expand and diversify platform and pipeline to include mRNA and gene correction therapeutics for central nervous system, […]